Monitor PiNACLE pivotal data release in mid-2027 and BLA submission timeline; the $80M placement provides near-term liquidity but dilutes existing holders. Watch for LYL273 Phase 1 data and End-of-Phase 1 FDA meeting in 2027.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma reported Q3 2026 net loss of $45.5M, wider than the $38.8M loss in Q3 2025, driven by increased R&D spending on clinical trials. The company announced updated ronde-cel data showing a 91% overall response rate and 77% complete response rate in the 3L+ PiNACLE trial, and completed an $80M private placement to extend cash runway into 2028.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $45.5M vs $38.8M in Q3 2025
- Revenue of $3K vs $15K in Q3 2025
- R&D expenses increased to $40.9M from $28.2M YoY
- Cash, equivalents and marketable securities of $194.0M as of Sep 30, 2026
- Completed $80.0M private placement in November 2026
- Updated ronde-cel data: 91% ORR, 77% CR rate in 3L+ PiNACLE trial
- PiNACLE pivotal data expected mid-2027, BLA submission H2 2027
- LYL273 technology transfer to LyFE completed; End-of-Phase 1 meeting with FDA expected 2027
Financial Impact
Net loss widened by $6.7M YoY; cash burn of ~$53M in Q3; $80M private placement extends runway into 2028
Risk Factors
- Clinical trial enrollment and data timing risks for PiNACLE and PiNACLE-H2H
- Regulatory approval risk for ronde-cel BLA
- Cash burn rate may require additional financing before 2028
- Dilution from $80M private placement
- Competition from approved CD19 CAR-T therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395800 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | Insider Cluster | $15.40 | awaiting T+1 | awaiting T+1 | $15.00 (−2.60%) |
Nov 5, 2026 today | Insider Buy | $15.40 | awaiting T+1 | awaiting T+1 | $15.00 (−2.60%) |
Nov 4, 2026 1d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Nov 4, 2026 1d ago | Press Release | $15.08 | awaiting T+1 | awaiting T+1 | $15.00 (−0.53%) |
Nov 4, 2026 1d ago | 8-K | $15.43 $15.00 | ▲ +2.79% | ▼ −1.62% | $15.00 (+2.79%) |
Nov 4, 2026 1d ago | Press Release | $15.43 $15.00 | ▼ −2.79% | ▲ +1.62% | $15.00 (−2.79%) |
Aug 25, 2026 10w ago | Insider Cluster | $14.80 $14.61 | ▼ −1.28% | ▼ −1.94% | $15.00 (+1.35%) |
Jul 22, 2026 15w ago | EFFECT | $12.84 $12.78 | ▼ −0.47% | ▲ +0.77% | $15.00 (+16.82%) |
Jun 15, 2026 20w ago | Insider Cluster | $12.44 $12.52 | ▲ +0.64% | ▲ +1.89% | $15.00 (+20.58%) |
Jun 12, 2026 20w ago | Press Release | $13.50 $13.55 | ▲ +0.37% | ▼ −1.39% | $15.00 (+11.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers